BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain Salazar R, Cruz-Hernández JJ, Sánchez-Valdivieso E, Rodríguez CA, Gómez-Bernal A, Barco E, Fonseca E, Portugal T, González-Sarmiento R. Cancer letters 233(1):172-7. FI: 3.741 (Q2) Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer Feliu J, Martín G, Castro J, Sundlov A, Rodríguez-Jaráiz A, Casado E, Lomas M, Madroñal C, Galán A, Belda C, González-Báron M. Cancer Chemotherapy and Pharmacology 58(4):527-31. FI: 2.654 (Q2) Trastuzumab and antiestrogen therapy: focus on mechanisms of actino and resístanse Ocaña A, Cruz JJ, Pandiella A. American Journal of Clinical Oncology 29(1):90-5. FI: 2.206 ¿Q3 Advanced breast cancer: chemotherapy phase III trials that change a standard Estevez LG, Tusquets I, Muñoz M, Adrover E, Rovira PS, Seguí MA, Rodríguez CA, Lescure AR, Ruiz M, Alvarez I, Mata JG. Anticancer Drugs 18(7):843-59. FI: 2.230 (Q3) Adjuvant endocrine therapies for premenopausal women Rodríguez Sánchez CA. Clinical & Translational Oncology 9(6):369-74. FI: 1.146 (Q4) Current controversies in the management of early breast cancer Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I. Clinical & Translational Oncology 9(6):375-38. FI: 1.146 (Q4) The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II and phase III trials Tusquets I, Estévez LG, Alvarez I, Muñoz M, Adrover E, Albanell J, Rodríguez C, Seguí MA, Rodríguez-Lescure A, Ruiz-Borrego M, García-Mata J, Lluch A. Clinical Breast Cancer 7(10):764-74. FI: 2.065 (Q3) Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients Ocaña A, Rodríguez-Barbero A, Pericacho M, Bellido L, Seijas R, López R, Delgado C, de Prado DS, Cruz-Hernández JJ, López-Novoa JM. Cancer letters 255(1):71-6. FI: 3.741 (Q2) Targetting receptor tyrosine kinases and their signal transduction routes in head and neck cancer Cruz JJ, Ocaña A, Del Barco E, Pandiella A. Annals of Oncology 18(3): 421-430. FI: 5.647 (Q1) Neuregulin expression modulates clinical response to herceptin in patients with metastatic breast cancer De Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. Journal of Clinical Oncology 25(19):2656-63. FI: 17.793 (Q1)
|
